PF 9601N is an inhibitor of monoamine oxidase B (MAO-B).1 It selectively inhibits MAO-B in mouse brain homogenates ex vivo (ID50 = 381 nmol/kg) and prevents MPTP-induced reductions in dopamine levels in the striatum of 8- to 9-week-old mice when administered at doses ranging from 29.5 to 8.47 µmol/kg. PF 9601N (0.027 µmol/kg) prevents MPTP-induced lesions in 9- to 10-month-old mice. It also increases the duration of contralateral rotational behavior induced by L-DOPA in a rat model of Parkinson’s disease induced by 6-OHDA when administered at doses of 40 and 60 mg/kg.2
1.Perez, V., and Unzeta, M.PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 miceNeurochem. Int.42(3)221-229(2003) 2.Prat, G., PÉrez, V., Rubi, A., et al.The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned ratsJ. Neural Transm. (Vienna)107(4)409-417(2000)